<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053077</url>
  </required_header>
  <id_info>
    <org_study_id>ClinDiab-05</org_study_id>
    <nct_id>NCT02053077</nct_id>
  </id_info>
  <brief_title>Risk Identification of the GlucoTab System in Routine Use</brief_title>
  <official_title>A Study to Identify Risks in Routine Use of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of risks of the GlucoTab system in routine use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to identify risks in routine use of the GlucoTab system for glycaemic management in
      non-critically ill patients with type 2 diabetes at general wards.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Identification of risks of the GlucoTab system in routine use assessed by the percentage of blood glucose values &lt;70 mg/dl and â‰¥300 mg/dl</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>medication / device interaction (e.g. corticosteroids, parenteral bolus nutrition) number of hypoglycaemic events day time of hypoglycaemic events risk factors for hypoglycaemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of re-initialisations of the GlucoTab decision support reasons of re-initialisations of GlucoTab decision support percentage GlucoTab treatment covers patient stay percentage of GlucoTab use per eligible patient with type 2 diabetes or new-onset hyperglycaemia per ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean daily blood glucose patient-day weighted mean blood glucose mean pre-breakfast blood glucose, mean pre-lunch blood glucose, mean pre-dinner blood glucose, mean bedtime blood glucose</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        non-critically ill patients with type 2 diabetes at general wards
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent obtained after being advised of the nature of the study

          -  type 2 diabetes or new-onset hyperglycaemia which require s.c. insulin therapy during
             hospital stay

          -  diabetes therapy supported by GlucoTab system

        Exclusion Criteria:

          -  type 1 diabetes mellitus

          -  intravenous insulin therapy

          -  hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require
             intravenous insulin therapy

          -  gestational diabetes or pregnancy

          -  known or suspected allergy to certain insulin types, named in the user manual

          -  total parenteral nutrition (TPN)

          -  any mental condition rendering the patient incapable of giving his consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R. Pieber, Univ.Prof.Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katharina M. Neubauer, MSc BSc</last_name>
    <phone>+4331638572841</phone>
    <email>katharina.neubauer@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharina M. Neubauer, MSc BSc</last_name>
      <phone>+4331638572841</phone>
      <email>katharina.neubauer@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Pieber Thomas, MD</investigator_full_name>
    <investigator_title>Univ. Prof. Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
